Abstract: A display substrate (20) and a display device (40). The display substrate (20) comprises a base substrate and a plurality of sub-pixels (100) located on the base substrate. Each sub-pixel (100) comprises a pixel circuit and a pixel electrode (134) electrically connected to the pixel circuit, and each pixel circuit comprises a driving sub-circuit. The pixel electrodes (134) each comprises an electrode body part (140) and a first electrode extension part (142) extending from the electrode body part (140). The display substrate (20) comprises first-type sub-pixels. The electrode body part (140) of each first-type sub-pixel (100) does not overlap a control electrode of the driving sub-circuit of the sub-pixel or an electrode part directly electrically connected to the control electrode, and the first electrode extension part (142) of each pixel electrode (134) at least partially overlaps the control electrode or the electrode part.

Abstract: A hot extrusion die for a special-shaped square pipe includes a die cavity sleeve with a special-shaped cavity. A hot extrusion mandrel is arranged in the die cavity sleeve. An area between the die cavity sleeve and the hot extrusion mandrel forms a die cavity hole. A first extrusion diversion hole and a second extrusion diversion hole are arranged below the die cavity hole. An integral centroid of the die cavity hole is located at a circle center of a radial cross section of the die cavity sleeve. Further disclosed is a hot extrusion integral forming method for a special-shaped square pipe, including: heating and expanding a blank material; heating the blank material again after expanding; performing hot extrusion on the blank material; and cooling the formed special-shaped square pipe in air to a room temperature, and inspecting surface quality and mechanical properties of the special-shaped square pipe.

Abstract: A collector 2-cyano-N-(substituted carbamoyl)acetamide compound in flotation of calcium-bearing minerals and a highly selective flotation reagent for the calcium-bearing minerals are provided. The highly selective flotation reagent includes the 2-cyano-N-(substituted carbamoyl)acetamide compound and an auxiliary collector. The 2-cyano-N-(substituted carbamoyl)acetamide compound has an excellent effect on flotation separation of the calcium-bearing minerals and a foaming performance. Dosage is further reduced and a flotation performance is improved by compounding the compound with the auxiliary collector. The flotation reagent can preferably separate fluorite from calcite by flotation, efficiently separates the fluorite and the calcite from scheelite under neutral condition (pH is about 7), effectively purifies rough scheelite concentrate and improves grade of scheelite concentrate. Meanwhile, the neutral flotation reduces influence on the environment.

Abstract: A method for video compression processing, an electronic device, and a storage medium. In the method for video compression processing, video compression is performed by using an end-to-end model trained with a single loss function, to obtain video compression information.

Abstract: A method for video compression processing, an electronic device, and a storage medium. In the method for video compression processing, video compression is performed by using an end-to-end model trained with a single loss function, to obtain video compression information.

Abstract: Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.

Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

Abstract: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

Abstract: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease

Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

Abstract: Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.

Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.